Lantern Pharma Stock News

AI penny stocks provide investors with higher-risk, higher-upside exposure to companies specializing in developing or utilizing artificial intelligence technology. Since these stocks trade at a rel

Fintel reports that ProPhase Labs, Inc. has filed a 13G form with the SEC disclosing ownership of 910,000 shares of Lantern Pharma Inc. (LTRN). This represents 8.4% of the company.

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.

DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine lea

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (�

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (�

Lantern Pharma Inc. (NASDAQ:LTRN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Nicole Leber – Investor Relations Panna Sharma – Chief Executive Officer David Ma

Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate, Finance & Administrative Coordinator Panna

DALLAS, April 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning

LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. Brain metastases in the U.S. can occur in 10-30% of all cancer cases and are diagnosed in o

Lantern Pharma Inc.'s (LTRN) CEO Panna Sharma on Q4 2021 Results - Earnings Call Transcript

The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdoid Tumor (ATRT), a form of cancer of the Central N

Lantern Pharma Inc (LTRN) shares closed today at 1.2% above its 52 week low of $6.89, giving the company a market cap of $77M. The stock is currently down 12.7% year-to-date, down 63.5% over the past 12 months, and down 53.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 18.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1016.1% The company's stock price performance over the past 12 months lags the peer average by 954.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

DALLAS, Jan. 4, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the

Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q3 2021 Results - Earnings Call Transcript